UnitedHealth to Drop Prior Authorization for 1,700 Services

UnitedHealth Group will eliminate prior authorization requirements for 1,700 medical services on October 1. The change applies to most of its commercial, Medicare Advantage, community, and individual-exchange plans, building on a company commitment to cut such requirements by 30% this year.

For patients, the policy shift promises fewer forms and faster care decisions. For investors, the key question is whether reduced bureaucracy will also lead to a more efficient and profitable company. UnitedHealthcare generated $86 billion in revenue in the second quarter but only $3.9 billion in operating profit, a slim 4.6% margin that leaves little room for cost increases if easier approvals drive higher medical service utilization.

UnitedHealth Stock Performance in 2026

The stock of UnitedHealth Group has been volatile this year. After a strong six-month rally fueled by earnings beats and analyst upgrades, enthusiasm cooled in July. The shares have gained 19% year-to-date and are up 34.7% over the past six months.

A significant jump occurred on July 16 following the company's second-quarter report. The stock reached $461.62, its highest level in about a year, after management raised full-year guidance and announced plans to buy back at least $5 billion worth of stock. Since that peak, however, the stock has pulled back by 15%, trading below $400 as investors remain cautious.

A Detailed Look at Q2 2026 Results

UnitedHealth's second-quarter results beat Wall Street expectations. The company reported revenue of $112 billion, slightly ahead of the $111.6 billion reported a year earlier. Adjusted earnings per share jumped to $6.38 from $4.08.

Key financial metrics from the quarter are shown below.

Medical costs fell to $75.4 billion from $78.6 billion a year ago, and the medical care ratio improved to 86.7% from 89.4%. UnitedHealthcare served 48.5 million people as of June 30. Management raised its 2026 outlook, now expecting adjusted EPS between $19.50 and $20.00.

Analyst Sentiment and Valuation

Analyst sentiment toward UnitedHealth stock is broadly favorable. Of the 26 analysts covering the stock, 19 recommend a "Strong Buy" and three suggest a "Moderate Buy," while four advise "Hold." The mean price target is $480.81, implying a potential 25% upside from recent levels.

The stock's valuation is seen as attractive. It trades at about 21.7 times forward earnings and 0.81 times forward sales, below both sector medians and its own five-year averages. The company also offers a dividend, having raised it for 16 consecutive years. The quarterly payout is $2.32 per share, providing an annual yield of 2.32%.

At a recent industry conference, UnitedHealth management said the turnaround is progressing, citing better Medicare Advantage performance and growing use of automation and AI to control costs. However, they also acknowledged pressure in parts of the commercial business and higher medical costs, including out-of-network arbitration expenses. The company expects full-year 2026 revenue to exceed $439 billion.